PHIO Phio Pharmaceuticals Corp.
Company Updates ·
The batch is a manufacturing milestone that supports the planned start of a Phase 2b trial in the first quarter of 2027. The company issued a press release announcing it on October 13, 2026.
Phio Pharmaceuticals said on September 14, 2026 that it reached a development milestone for PH-762, including the submission of materials to the FDA and a planned Phase 2b neoadjuvant study.
Phio Pharmaceuticals increased its board to six members and appointed R. Todd Plott, M.D., effective July 20, 2026, to serve until the 2026 annual meeting of stockholders.
Phio set up an at-the-market program that lets it sell up to $6,360,000 of common stock through H.C. Wainwright & Co., LLC, with a 3.0% commission. The size is capped because its public float is only $19,080,217, and its auditors have raised a going concern doubt.
Holders exercised existing warrants, most at a reduced $2.05 per share, in return for new Series A Warrants. Phio expects total gross proceeds of approximately $13.4 million before fees.
Phio sold 610,000 shares at $3.00 per share and issued short-term warrants for up to 1,220,000 shares in a concurrent private placement. Net proceeds are approximately $1.6 million, after a placement agent fee of 7.5% plus a 1.0% management fee.
Phio Pharmaceuticals Corp. is a clinical stage biopharmaceutical company developing immuno-oncology therapeutics based on its proprietary INTASYL small interfering RNA gene silencing technology. INTASYL compounds are chemically modified siRNAs designed to silence genes that tumors use to evade the immune system, and the company says they can be delivered to a broad range of cell types without specialized formulations or delivery systems. Its lead compound, PH-762, is designed to reduce PD-1 expression and is being evaluated in a U.S. multi-center Phase 1b trial using intratumoral injection in cutaneous squamous cell carcinoma, melanoma and Merkel cell carcinoma. The study was fully enrolled in November 2025 with 22 patients, and an FDA submission on next steps in clinical study design is targeted for the second quarter of 2026. A second compound, PH-894, is designed to silence BRD4. The company has completed the IND-enabling studies for PH-894 but elected to defer its IND submission while it advances PH-762 in the U.S.
| Product or program | What it is | Stage |
|---|---|---|
| PH-762 | INTASYL compound designed to reduce PD-1 expression, given by intratumoral injection | Phase 1b trial fully enrolled November 2025; FDA submission targeted second quarter 2026 |
| PH-894 | INTASYL compound designed to silence BRD4 in T cells and tumor cells | IND-enabling studies completed; IND submission deferred |
| Line | FY2025 | FY2024 |
|---|---|---|
| Research and development | $4.6 million | $3.6 million |
| Net income (loss) | -$8.7 million | -$7.2 million |
| Cash from operations | -$8.0 million | -$7.1 million |
| Cash and equivalents | $21.0 million | $5.4 million |
Our latest story on this, dated Apr 8, 2026: "Phio Pharmaceuticals sets up $6,360,000 at-the-market program". The story links the filing or release it is based on. Read the story.
Our latest story on this, dated Apr 8, 2026: "Phio Pharmaceuticals sets up $6,360,000 at-the-market program". The story links the filing or release it is based on. Read the story.
Phio Pharmaceuticals Corp. trades under the ticker PHIO on NASDAQ.
Phio Pharmaceuticals Corp. is listed on NASDAQ.
The SEC Central Index Key (CIK) for Phio Pharmaceuticals Corp. is 1533040. Its filings are on SEC EDGAR.
11,617,250 shares as of 2026-08-04, per the cover page of its 10-Q filed 2026-08-06.
Our directory records Phio Pharmaceuticals Corp. under United States.
Our directory classifies Phio Pharmaceuticals Corp. as: Biotechnology. This is a directory classification, not a description of the pipeline.
The ISIN recorded for Phio Pharmaceuticals Corp. is US71880W5013.
aibio.space lists Phio Pharmaceuticals Corp. among 2,820 public biotech companies and publishes its news here as stories appear.
SEC records list its state or country of incorporation as DE.
Phio Pharmaceuticals Corp. is a clinical stage biopharmaceutical company developing immuno-oncology therapeutics based on its proprietary INTASYL small interfering RNA gene silencing technology. INTASYL compounds are chemically modified siRNAs designed to silence genes that tumors use to evade the immune system, and the company says they can be delivered to a broad range of cell types without specialized formulations or delivery systems.
PH-762: INTASYL compound designed to reduce PD-1 expression, given by intratumoral injection Stage: Phase 1b trial fully enrolled November 2025; FDA submission targeted second quarter 2026.
PH-894: INTASYL compound designed to silence BRD4 in T cells and tumor cells Stage: IND-enabling studies completed; IND submission deferred.
Phio Pharmaceuticals Corp. reported a net loss of $8.7 million for the fiscal year ended Dec 31, 2025, and used $8.0 million of cash in operations, per its annual report to the SEC.
Reported a financing. SEC Form 8-K (Items 1.01,9.01). Source
Reported substantial doubt about its ability to continue as a going concern. SEC Form 10-K. Source
Reported a financing. SEC Form 8-K (Items 1.01,3.02,8.01,9.01). Source
Reported a change of independent auditor. SEC Form 8-K (Items 4.01,9.01). Source
Who manages this page This page is managed by aibio.space. The company does not run, edit or pay for this page. News, desk views and Investor Ranks are written and managed independently by aibio.space under our editorial and analytical judgment. Opinion only, not investment advice. How we work · Terms · Request a correction
aibio